Yes, you can screen models in vitro before choosing an O-PDX model for your in vivo study. Certis offers a wide variety of in vitro screens depending on your study needs, including immunohistochemistry, IC50 dose response curve and spectral flow cytometry analysis.
Alternatively, the CertisAI™ Predictive Oncology platform is a pan-cancer solution that enables cancer researchers to effectively replace many discovery screening studies with in silico predictions and can predict which in vitro or in vivo models are most likely to respond to your compound or combination therapy.